NSEPress Release21 Oct 2026 · 21 Oct 2026, 02:40 pm

Press Release

Nureca Limited · NURECA

✦ AI Summary▲ PositiveResults

Nureca Limited has reported its unaudited consolidated results for the quarter and half year ended 30 September 2026, with revenue from operations growing 55% year on year to ₹58.53 crore and profit after tax increasing 12% to ₹4.05 crore.

Analysis Scores

Earnings Impact8/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Nureca Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Nureca records highest quarterly revenue in last 20 quarters ; Q2 revenue rises 55% to Rs. 58.53 crore ".

Attachments (1)

📄

NURECA_21102026144051_StockExchnageIntimationPressRelease21102026.pdf

pdf

Download →
View document text
www.nureca.com Dated – 21st October, 2026 BSE LIMITED NATIONAL STOCK EXCHANGE OF INDIA Corporate Relations Department LIMITED Phiroze Jeejeebhoy Towers Listing Department Dalal Street, Fort Exchange Plaza, 5th Floor, Plot no. C/1 Mumbai-400001 G Block, Bandra Kurla Complex, Bandra (E) Scrip code: 543264 Mumbai-400051 Scrip Code: NURECA Subject: Press Release Dear Sir, Please find attached herewith Press Release titled “Nureca records highest quarterly revenue in last 20 quarters; Q2 revenue rises 55% to ₹58.53 crore.” This is for your information and record please. Thanking You, Yours Sincerely, For Nureca Limited (Nishu Kansal) Company Secretary & Compliance Officer M.No. A33372 NURECA LIMITED Correspondence Office: SCO 6-7-8, 1st Floor, Madhya Marg, Sector 9-D, Chandigarh, India - 160009 Registered Office: Andheri West B-205, Bldg -42, B wing, Dhanashree heights, Azad Nagar Sangam CHS, Andheri West, Mumbai – 400053 Phone No. +91-172-5292900, CIN: L24304MH2016PLC320868 Press Release Nureca records highest quarterly revenue in last 20 quarters; Q2 revenue rises 55% to ₹58.53 crore Chandigarh, 21 October 2026 — Nureca Limited (NSE: NURECA; BSE: 543264), the parent company of the Dr Trust, Dr Physio and Trumom brands, today announced its unaudited consolidated results for the quarter and half year ended 30 September 2026. Q2 FY27 highlights ● Revenue from operations grew 55% year on year to ₹58.53 crore from ₹37.74 crore, the Company’s highest quarterly revenue in 20 quarters. ● Operating profit grew 60% to ₹5.23 crore from ₹3.27 crore, the highest in 19 consecutive quarters. ● Profit before tax increased 20% to ₹5.52 crore from ₹4.60 crore. ● Profit after tax increased 12% to ₹4.05 crore from ₹3.63 crore. ● Earnings per share rose to ₹4.25 from ₹3.63. H1 FY27 highlights ● Revenue from operations grew 37% year on year to ₹98.87 crore from ₹71.92 crore. ● Profit after tax grew 60% to ₹7.12 crore from ₹4.44 crore. Commentary Revenue growth during the quarter was broad-based across the Company’s e-commerce, quick-commerce and offline distribution channels. Operating profit grew ahead of revenue, reflecting the Company’s largely fixed cost base, with employee costs declining as a proportion of revenue. Online Sales increased by 55% (YoY) & 55% (QoQ). Offline revenue increased to 90%(YoY) & 49% (QoQ). Ecommerce sales contribute to 88% of revenue. Working capital increased during the half year, reflecting inventory and channel positioning ahead of the festive and winter season. The Company remains debt-free. About Nureca Limited Nureca Limited is a consumer healthcare company with brands including Dr Trust, Dr Physio and Trumom. Its products span home diagnostics, fitness and body metrics, massage therapy, orthopaedic support, mother and baby care, and home wellness. The Company serves consumers through online marketplaces, quick-commerce platforms, direct-to-consumer channels and offline trade across India. Dr Trust 360 connects the Company’s smart devices with health data and personalised insights. Nureca is also expanding its manufacturing base in Punjab for medical devices, healthcare consumables and hygiene products. For further information: investor@nureca.com This release contains unaudited financial information that is subject to limited review. Saurabh Goyal Chairman and Managing Director Nureca Limited